The BET PROTAC inhibitor GNE-987 displays anti-tumor effects by targeting super-enhancers regulated gene in osteosarcoma
Osteosarcoma (OS) is one of the most common primary malignant tumors of bone in children, which develops from osteoblasts and typically occurs during the rapid growth phase of the bone. Recently, Super-Enhancers(SEs)have been reported to play a crucial role in osteosarcoma growth and metastasis. The...
Saved in:
| Published in | BMC cancer Vol. 24; no. 1; pp. 928 - 16 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
01.08.2024
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Osteosarcoma (OS) is one of the most common primary malignant tumors of bone in children, which develops from osteoblasts and typically occurs during the rapid growth phase of the bone. Recently, Super-Enhancers(SEs)have been reported to play a crucial role in osteosarcoma growth and metastasis. Therefore, there is an urgent need to identify specific targeted inhibitors of SEs to assist clinical therapy. This study aimed to elucidate the role of BRD4 inhibitor GNE-987 targeting SEs in OS and preliminarily explore its mechanism.
We evaluated changes in osteosarcoma cells following treatment with a BRD4 inhibitor GNE-987. We assessed the anti-tumor effect of GNE-987 in vitro and in vivo by Western blot, CCK8, flow cytometry detection, clone formation, xenograft tumor size measurements, and Ki67 immunohistochemical staining, and combined ChIP-seq with RNA-seq techniques to find its anti-tumor mechanism.
In this study, we found that extremely low concentrations of GNE-987(2-10 nM) significantly reduced the proliferation and survival of OS cells by degrading BRD4. In addition, we found that GNE-987 markedly induced cell cycle arrest and apoptosis in OS cells. Further study indicated that VHL was critical for GNE-987 to exert its antitumor effect in OS cells. Consistent with in vitro results, GNE-987 administration significantly reduced tumor size in xenograft models with minimal toxicity, and partially degraded the BRD4 protein. KRT80 was identified through analysis of the RNA-seq and ChIP-seq data. U2OS HiC analysis suggested a higher frequency of chromatin interactions near the KRT80 binding site. The enrichment of H3K27ac modification at KRT80 was significantly reduced after GNE-987 treatment. KRT80 was identified as playing an important role in OS occurrence and development.
This research revealed that GNE-987 selectively degraded BRD4 and disrupted the transcriptional regulation of oncogenes in OS. GNE-987 has the potential to affect KRT80 against OS. |
|---|---|
| AbstractList | Osteosarcoma (OS) is one of the most common primary malignant tumors of bone in children, which develops from osteoblasts and typically occurs during the rapid growth phase of the bone. Recently, Super-Enhancers(SEs)have been reported to play a crucial role in osteosarcoma growth and metastasis. Therefore, there is an urgent need to identify specific targeted inhibitors of SEs to assist clinical therapy. This study aimed to elucidate the role of BRD4 inhibitor GNE-987 targeting SEs in OS and preliminarily explore its mechanism. We evaluated changes in osteosarcoma cells following treatment with a BRD4 inhibitor GNE-987. We assessed the anti-tumor effect of GNE-987 in vitro and in vivo by Western blot, CCK8, flow cytometry detection, clone formation, xenograft tumor size measurements, and Ki67 immunohistochemical staining, and combined ChIP-seq with RNA-seq techniques to find its anti-tumor mechanism. In this study, we found that extremely low concentrations of GNE-987(2-10 nM) significantly reduced the proliferation and survival of OS cells by degrading BRD4. In addition, we found that GNE-987 markedly induced cell cycle arrest and apoptosis in OS cells. Further study indicated that VHL was critical for GNE-987 to exert its antitumor effect in OS cells. Consistent with in vitro results, GNE-987 administration significantly reduced tumor size in xenograft models with minimal toxicity, and partially degraded the BRD4 protein. KRT80 was identified through analysis of the RNA-seq and ChIP-seq data. U2OS HiC analysis suggested a higher frequency of chromatin interactions near the KRT80 binding site. The enrichment of H3K27ac modification at KRT80 was significantly reduced after GNE-987 treatment. KRT80 was identified as playing an important role in OS occurrence and development. This research revealed that GNE-987 selectively degraded BRD4 and disrupted the transcriptional regulation of oncogenes in OS. GNE-987 has the potential to affect KRT80 against OS. BackgroundOsteosarcoma (OS) is one of the most common primary malignant tumors of bone in children, which develops from osteoblasts and typically occurs during the rapid growth phase of the bone. Recently, Super-Enhancers(SEs)have been reported to play a crucial role in osteosarcoma growth and metastasis. Therefore, there is an urgent need to identify specific targeted inhibitors of SEs to assist clinical therapy. This study aimed to elucidate the role of BRD4 inhibitor GNE-987 targeting SEs in OS and preliminarily explore its mechanism.MethodsWe evaluated changes in osteosarcoma cells following treatment with a BRD4 inhibitor GNE-987. We assessed the anti-tumor effect of GNE-987 in vitro and in vivo by Western blot, CCK8, flow cytometry detection, clone formation, xenograft tumor size measurements, and Ki67 immunohistochemical staining, and combined ChIP-seq with RNA-seq techniques to find its anti-tumor mechanism.ResultsIn this study, we found that extremely low concentrations of GNE-987(2–10 nM) significantly reduced the proliferation and survival of OS cells by degrading BRD4. In addition, we found that GNE-987 markedly induced cell cycle arrest and apoptosis in OS cells. Further study indicated that VHL was critical for GNE-987 to exert its antitumor effect in OS cells. Consistent with in vitro results, GNE-987 administration significantly reduced tumor size in xenograft models with minimal toxicity, and partially degraded the BRD4 protein. KRT80 was identified through analysis of the RNA-seq and ChIP-seq data. U2OS HiC analysis suggested a higher frequency of chromatin interactions near the KRT80 binding site. The enrichment of H3K27ac modification at KRT80 was significantly reduced after GNE-987 treatment. KRT80 was identified as playing an important role in OS occurrence and development.ConclusionsThis research revealed that GNE-987 selectively degraded BRD4 and disrupted the transcriptional regulation of oncogenes in OS. GNE-987 has the potential to affect KRT80 against OS. Osteosarcoma (OS) is one of the most common primary malignant tumors of bone in children, which develops from osteoblasts and typically occurs during the rapid growth phase of the bone. Recently, Super-Enhancers(SEs)have been reported to play a crucial role in osteosarcoma growth and metastasis. Therefore, there is an urgent need to identify specific targeted inhibitors of SEs to assist clinical therapy. This study aimed to elucidate the role of BRD4 inhibitor GNE-987 targeting SEs in OS and preliminarily explore its mechanism. We evaluated changes in osteosarcoma cells following treatment with a BRD4 inhibitor GNE-987. We assessed the anti-tumor effect of GNE-987 in vitro and in vivo by Western blot, CCK8, flow cytometry detection, clone formation, xenograft tumor size measurements, and Ki67 immunohistochemical staining, and combined ChIP-seq with RNA-seq techniques to find its anti-tumor mechanism. In this study, we found that extremely low concentrations of GNE-987(2-10 nM) significantly reduced the proliferation and survival of OS cells by degrading BRD4. In addition, we found that GNE-987 markedly induced cell cycle arrest and apoptosis in OS cells. Further study indicated that VHL was critical for GNE-987 to exert its antitumor effect in OS cells. Consistent with in vitro results, GNE-987 administration significantly reduced tumor size in xenograft models with minimal toxicity, and partially degraded the BRD4 protein. KRT80 was identified through analysis of the RNA-seq and ChIP-seq data. U2OS HiC analysis suggested a higher frequency of chromatin interactions near the KRT80 binding site. The enrichment of H3K27ac modification at KRT80 was significantly reduced after GNE-987 treatment. KRT80 was identified as playing an important role in OS occurrence and development. This research revealed that GNE-987 selectively degraded BRD4 and disrupted the transcriptional regulation of oncogenes in OS. GNE-987 has the potential to affect KRT80 against OS. Abstract Background Osteosarcoma (OS) is one of the most common primary malignant tumors of bone in children, which develops from osteoblasts and typically occurs during the rapid growth phase of the bone. Recently, Super-Enhancers(SEs)have been reported to play a crucial role in osteosarcoma growth and metastasis. Therefore, there is an urgent need to identify specific targeted inhibitors of SEs to assist clinical therapy. This study aimed to elucidate the role of BRD4 inhibitor GNE-987 targeting SEs in OS and preliminarily explore its mechanism. Methods We evaluated changes in osteosarcoma cells following treatment with a BRD4 inhibitor GNE-987. We assessed the anti-tumor effect of GNE-987 in vitro and in vivo by Western blot, CCK8, flow cytometry detection, clone formation, xenograft tumor size measurements, and Ki67 immunohistochemical staining, and combined ChIP-seq with RNA-seq techniques to find its anti-tumor mechanism. Results In this study, we found that extremely low concentrations of GNE-987(2–10 nM) significantly reduced the proliferation and survival of OS cells by degrading BRD4. In addition, we found that GNE-987 markedly induced cell cycle arrest and apoptosis in OS cells. Further study indicated that VHL was critical for GNE-987 to exert its antitumor effect in OS cells. Consistent with in vitro results, GNE-987 administration significantly reduced tumor size in xenograft models with minimal toxicity, and partially degraded the BRD4 protein. KRT80 was identified through analysis of the RNA-seq and ChIP-seq data. U2OS HiC analysis suggested a higher frequency of chromatin interactions near the KRT80 binding site. The enrichment of H3K27ac modification at KRT80 was significantly reduced after GNE-987 treatment. KRT80 was identified as playing an important role in OS occurrence and development. Conclusions This research revealed that GNE-987 selectively degraded BRD4 and disrupted the transcriptional regulation of oncogenes in OS. GNE-987 has the potential to affect KRT80 against OS. Osteosarcoma (OS) is one of the most common primary malignant tumors of bone in children, which develops from osteoblasts and typically occurs during the rapid growth phase of the bone. Recently, Super-Enhancers(SEs)have been reported to play a crucial role in osteosarcoma growth and metastasis. Therefore, there is an urgent need to identify specific targeted inhibitors of SEs to assist clinical therapy. This study aimed to elucidate the role of BRD4 inhibitor GNE-987 targeting SEs in OS and preliminarily explore its mechanism.BACKGROUNDOsteosarcoma (OS) is one of the most common primary malignant tumors of bone in children, which develops from osteoblasts and typically occurs during the rapid growth phase of the bone. Recently, Super-Enhancers(SEs)have been reported to play a crucial role in osteosarcoma growth and metastasis. Therefore, there is an urgent need to identify specific targeted inhibitors of SEs to assist clinical therapy. This study aimed to elucidate the role of BRD4 inhibitor GNE-987 targeting SEs in OS and preliminarily explore its mechanism.We evaluated changes in osteosarcoma cells following treatment with a BRD4 inhibitor GNE-987. We assessed the anti-tumor effect of GNE-987 in vitro and in vivo by Western blot, CCK8, flow cytometry detection, clone formation, xenograft tumor size measurements, and Ki67 immunohistochemical staining, and combined ChIP-seq with RNA-seq techniques to find its anti-tumor mechanism.METHODSWe evaluated changes in osteosarcoma cells following treatment with a BRD4 inhibitor GNE-987. We assessed the anti-tumor effect of GNE-987 in vitro and in vivo by Western blot, CCK8, flow cytometry detection, clone formation, xenograft tumor size measurements, and Ki67 immunohistochemical staining, and combined ChIP-seq with RNA-seq techniques to find its anti-tumor mechanism.In this study, we found that extremely low concentrations of GNE-987(2-10 nM) significantly reduced the proliferation and survival of OS cells by degrading BRD4. In addition, we found that GNE-987 markedly induced cell cycle arrest and apoptosis in OS cells. Further study indicated that VHL was critical for GNE-987 to exert its antitumor effect in OS cells. Consistent with in vitro results, GNE-987 administration significantly reduced tumor size in xenograft models with minimal toxicity, and partially degraded the BRD4 protein. KRT80 was identified through analysis of the RNA-seq and ChIP-seq data. U2OS HiC analysis suggested a higher frequency of chromatin interactions near the KRT80 binding site. The enrichment of H3K27ac modification at KRT80 was significantly reduced after GNE-987 treatment. KRT80 was identified as playing an important role in OS occurrence and development.RESULTSIn this study, we found that extremely low concentrations of GNE-987(2-10 nM) significantly reduced the proliferation and survival of OS cells by degrading BRD4. In addition, we found that GNE-987 markedly induced cell cycle arrest and apoptosis in OS cells. Further study indicated that VHL was critical for GNE-987 to exert its antitumor effect in OS cells. Consistent with in vitro results, GNE-987 administration significantly reduced tumor size in xenograft models with minimal toxicity, and partially degraded the BRD4 protein. KRT80 was identified through analysis of the RNA-seq and ChIP-seq data. U2OS HiC analysis suggested a higher frequency of chromatin interactions near the KRT80 binding site. The enrichment of H3K27ac modification at KRT80 was significantly reduced after GNE-987 treatment. KRT80 was identified as playing an important role in OS occurrence and development.This research revealed that GNE-987 selectively degraded BRD4 and disrupted the transcriptional regulation of oncogenes in OS. GNE-987 has the potential to affect KRT80 against OS.CONCLUSIONSThis research revealed that GNE-987 selectively degraded BRD4 and disrupted the transcriptional regulation of oncogenes in OS. GNE-987 has the potential to affect KRT80 against OS. Background Osteosarcoma (OS) is one of the most common primary malignant tumors of bone in children, which develops from osteoblasts and typically occurs during the rapid growth phase of the bone. Recently, Super-Enhancers(SEs)have been reported to play a crucial role in osteosarcoma growth and metastasis. Therefore, there is an urgent need to identify specific targeted inhibitors of SEs to assist clinical therapy. This study aimed to elucidate the role of BRD4 inhibitor GNE-987 targeting SEs in OS and preliminarily explore its mechanism. Methods We evaluated changes in osteosarcoma cells following treatment with a BRD4 inhibitor GNE-987. We assessed the anti-tumor effect of GNE-987 in vitro and in vivo by Western blot, CCK8, flow cytometry detection, clone formation, xenograft tumor size measurements, and Ki67 immunohistochemical staining, and combined ChIP-seq with RNA-seq techniques to find its anti-tumor mechanism. Results In this study, we found that extremely low concentrations of GNE-987(2-10 nM) significantly reduced the proliferation and survival of OS cells by degrading BRD4. In addition, we found that GNE-987 markedly induced cell cycle arrest and apoptosis in OS cells. Further study indicated that VHL was critical for GNE-987 to exert its antitumor effect in OS cells. Consistent with in vitro results, GNE-987 administration significantly reduced tumor size in xenograft models with minimal toxicity, and partially degraded the BRD4 protein. KRT80 was identified through analysis of the RNA-seq and ChIP-seq data. U2OS HiC analysis suggested a higher frequency of chromatin interactions near the KRT80 binding site. The enrichment of H3K27ac modification at KRT80 was significantly reduced after GNE-987 treatment. KRT80 was identified as playing an important role in OS occurrence and development. Conclusions This research revealed that GNE-987 selectively degraded BRD4 and disrupted the transcriptional regulation of oncogenes in OS. GNE-987 has the potential to affect KRT80 against OS. Keywords: OS, BRD4, SEs, PROTAC, KRT80 |
| ArticleNumber | 928 |
| Audience | Academic |
| Author | Pan, Jian Yang, Chun Fang, Fang Li, Xiaolu Chen, Yanling Zhang, Zimu Zhuo, Ran Yu, Juanjuan Wu, Di Wang, Jianwei Xie, Yi Li, Tiandan Hu, Xiaohan Li, Gen Yin, Hongli |
| Author_xml | – sequence: 1 givenname: Di surname: Wu fullname: Wu, Di organization: Institute of Pediatric Research, Children's Hospital of Soochow University, No.92 Zhongnan Street, SIP, Suzhou, 215003, China – sequence: 2 givenname: Hongli surname: Yin fullname: Yin, Hongli organization: Institute of Pediatric Research, Children's Hospital of Soochow University, No.92 Zhongnan Street, SIP, Suzhou, 215003, China – sequence: 3 givenname: Chun surname: Yang fullname: Yang, Chun organization: Institute of Pediatric Research, Children's Hospital of Soochow University, No.92 Zhongnan Street, SIP, Suzhou, 215003, China – sequence: 4 givenname: Zimu surname: Zhang fullname: Zhang, Zimu organization: Institute of Pediatric Research, Children's Hospital of Soochow University, No.92 Zhongnan Street, SIP, Suzhou, 215003, China – sequence: 5 givenname: Fang surname: Fang fullname: Fang, Fang organization: Institute of Pediatric Research, Children's Hospital of Soochow University, No.92 Zhongnan Street, SIP, Suzhou, 215003, China – sequence: 6 givenname: Jianwei surname: Wang fullname: Wang, Jianwei organization: Institute of Pediatric Research, Children's Hospital of Soochow University, No.92 Zhongnan Street, SIP, Suzhou, 215003, China – sequence: 7 givenname: Xiaolu surname: Li fullname: Li, Xiaolu organization: Institute of Pediatric Research, Children's Hospital of Soochow University, No.92 Zhongnan Street, SIP, Suzhou, 215003, China – sequence: 8 givenname: Yi surname: Xie fullname: Xie, Yi organization: Institute of Pediatric Research, Children's Hospital of Soochow University, No.92 Zhongnan Street, SIP, Suzhou, 215003, China – sequence: 9 givenname: Xiaohan surname: Hu fullname: Hu, Xiaohan organization: Institute of Pediatric Research, Children's Hospital of Soochow University, No.92 Zhongnan Street, SIP, Suzhou, 215003, China – sequence: 10 givenname: Ran surname: Zhuo fullname: Zhuo, Ran organization: Institute of Pediatric Research, Children's Hospital of Soochow University, No.92 Zhongnan Street, SIP, Suzhou, 215003, China – sequence: 11 givenname: Yanling surname: Chen fullname: Chen, Yanling organization: Institute of Pediatric Research, Children's Hospital of Soochow University, No.92 Zhongnan Street, SIP, Suzhou, 215003, China – sequence: 12 givenname: Juanjuan surname: Yu fullname: Yu, Juanjuan organization: Institute of Pediatric Research, Children's Hospital of Soochow University, No.92 Zhongnan Street, SIP, Suzhou, 215003, China – sequence: 13 givenname: Tiandan surname: Li fullname: Li, Tiandan organization: Institute of Pediatric Research, Children's Hospital of Soochow University, No.92 Zhongnan Street, SIP, Suzhou, 215003, China – sequence: 14 givenname: Gen surname: Li fullname: Li, Gen email: ligen925@yeah.net organization: Institute of Pediatric Research, Children's Hospital of Soochow University, No.92 Zhongnan Street, SIP, Suzhou, 215003, China. ligen925@yeah.net – sequence: 15 givenname: Jian surname: Pan fullname: Pan, Jian email: panjian2008@163.com organization: Institute of Pediatric Research, Children's Hospital of Soochow University, No.92 Zhongnan Street, SIP, Suzhou, 215003, China. panjian2008@163.com |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39090568$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkl1v0zAUhiM0xD7gD3CBIiEhuMiwEzuxr1Cpyqg0MTR6bznOSeIqtTvbQeu_x2tH1SDkC1vHz3ksH72XyZmxBpLkLUbXGLPys8c5YzRDOclwXnKc7V4kF5hUOMsJqs5OzufJpfdrhHDFEHuVnBcccURLdpE8rnpIvy5W6c_7u9VsnmrT61oH69KbH4uMsypttN8OcudTaYLOwriJd9C2oIJP610apOsgaNOlftyCy8D00ihwPnXQjYMM0KQdGIjm1PoA1kun7Ea-Tl62cvDw5nm_SlbfFqv59-z27mY5n91mimIUspLLhiMJeYmavJAKU0LiTmqOJaqbitIC1ZSBIiWn0LBC1VjVpOKtyltOi6tkedA2Vq7F1umNdDthpRb7gnWdkC5oNYBAZS5bybiCUhGEKYtiUmJZYNwQRVR0fTm4tmO9gUaBCU4OE-n0xuhedPa3wDjnOacsGj4-G5x9GMEHsdFewTBIA3b0okCsKihBeRHR9_-gazs6E0cVKR6FGEfsSHUy_kCb1saH1ZNUzBiKKsr2ruv_UHE1sNEqhqrVsT5p-DRpiEyAx9DJ0Xux_HU_ZT-csD3IIfTeDmPQ1vgpmB9A5az3Dtrj5DAST4EWh0CLGGixD7TYxaZ3pzM_tvxNcPEH1XDvlg |
| Cites_doi | 10.1016/j.ejca.2017.09.036 10.1186/s13046-019-1246-4 10.1038/s41571-022-00682-6 10.1186/s40659-017-0124-9 10.1038/s41571-021-00519-8 10.1002/ijc.29269 10.1038/s41594-018-0102-0 10.1038/s41419-018-1030-y 10.1038/s41591-019-0376-8 10.1016/j.ejmech.2019.111633 10.1016/S1470-2045(21)00387-9 10.1186/s12943-021-01453-0 10.1158/1541-7786.MCR-19-0470 10.1084/jem.20190668 10.1038/s41467-023-40061-y 10.1186/s13046-021-01974-y 10.1007/s00280-022-04483-7 10.1038/s41586-020-1930-8 10.1016/j.suronc.2009.05.002 10.1038/s41401-018-0187-3 10.1038/nature16508 10.3390/ijms20184482 10.3892/ol.2020.11855 10.1200/JCO.2008.14.0095 10.1038/bjc.2014.585 10.1016/j.jiph.2018.09.009 10.1053/j.gastro.2019.10.009 10.1093/nar/gkac778 10.1186/s13046-023-02615-2 10.1002/cmdc.202100113 10.1038/s41419-019-2022-2 10.1155/2022/7912484 10.1016/S1470-2045(16)30214-5 10.1002/cmdc.201900497 10.1016/j.tig.2018.11.007 10.1097/PAP.0000000000000293 10.1136/gutjnl-2016-311818 10.1200/JCO.2011.38.4420 10.1186/s13046-022-02428-9 10.1186/s13578-023-01088-2 10.1002/jso.21140 10.1186/s12951-021-01028-7 10.1039/D2CS00387B 10.1038/s41422-020-0370-1 10.1038/s41467-020-20378-8 10.1158/2159-8290.CD-17-0605 10.1002/advs.202207439 10.1016/j.cell.2017.02.015 10.1016/j.biopha.2020.109941 10.1038/s41467-019-09676-y 10.1186/s13578-022-00769-8 10.1126/science.aaa3247 10.1136/gutjnl-2019-318506 10.1038/s10038-020-0795-x 10.1186/s12943-018-0915-9 10.1016/j.cell.2013.09.053 10.1002/cam4.6040 10.1093/neuonc/noaa084 10.1016/j.molcel.2005.06.027 10.15252/emmm.201809408 10.1038/s41556-020-0522-z 10.1158/1078-0432.CCR-19-1418 10.1158/2159-8290.CD-16-0217 |
| ContentType | Journal Article |
| Copyright | 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 2024 |
| Copyright_xml | – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 2024 |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12885-024-12691-y |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Gale In Context: Science ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2407 |
| EndPage | 16 |
| ExternalDocumentID | oai_doaj_org_article_062afa89ce6c401580b5461a311d4c4c A803545823 10_1186_s12885_024_12691_y 39090568 |
| Genre | Journal Article |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GrantInformation_xml | – fundername: Jiangsu Province's science and technology support program (Social Development) project grantid: BE2021657 – fundername: National Outstanding Youth Cultivation Program Project grantid: YYJQ004 – fundername: National Natural Science Foundation grantid: 81971867 – fundername: National Natural Science Foundation grantid: 82141110 – fundername: the Science and Technology Development Project of Suzhou City grantid: SKJY2021112 – fundername: the Science and Technology Development Project of Suzhou City grantid: SKJY2021111 – fundername: Natural Science Foundation of Jiangsu Province grantid: BK20220047 – fundername: Suzhou Health Talent Training Project grantid: GSWS2021028 – fundername: the Science and Technology Development Project of Suzhou City grantid: SKJY2021109 – fundername: the Science and Technology Development Project of Suzhou City grantid: SKY2022182 |
| GroupedDBID | --- -A0 0R~ 23N 2WC 3V. 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS ECM EIF EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 LGEZI LOTEE M1P M~E NADUK NPM NXXTH O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX CITATION AFGXO 7TO 7XB 8FK AZQEC DWQXO H94 K9. M48 PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c510t-69ad90ae260d23ac154423a4b91a0bd75530b58ec4695ed83cb1cb479fc2f953 |
| IEDL.DBID | RPM |
| ISSN | 1471-2407 |
| IngestDate | Tue Oct 22 15:14:39 EDT 2024 Tue Sep 17 21:29:00 EDT 2024 Sat Oct 26 04:30:55 EDT 2024 Thu Oct 10 22:13:27 EDT 2024 Wed Aug 14 18:52:15 EDT 2024 Tue Nov 12 23:36:54 EST 2024 Sat Sep 28 21:35:03 EDT 2024 Tue Aug 20 22:14:21 EDT 2024 Thu Sep 12 20:40:13 EDT 2024 Sat Nov 02 11:56:40 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | SEs KRT80 OS PROTAC BRD4 |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it.The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c510t-69ad90ae260d23ac154423a4b91a0bd75530b58ec4695ed83cb1cb479fc2f953 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292958/ |
| PMID | 39090568 |
| PQID | 3091291102 |
| PQPubID | 44074 |
| PageCount | 16 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_062afa89ce6c401580b5461a311d4c4c pubmedcentral_primary_oai_pubmedcentral_nih_gov_11292958 proquest_miscellaneous_3087354023 proquest_journals_3091291102 gale_infotracmisc_A803545823 gale_infotracacademiconefile_A803545823 gale_incontextgauss_ISR_A803545823 gale_healthsolutions_A803545823 crossref_primary_10_1186_s12885_024_12691_y pubmed_primary_39090568 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-08-01 |
| PublicationDateYYYYMMDD | 2024-08-01 |
| PublicationDate_xml | – month: 08 year: 2024 text: 2024-08-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC cancer |
| PublicationTitleAlternate | BMC Cancer |
| PublicationYear | 2024 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | Y Perone (12691_CR63) 2019; 10 D Chen (12691_CR11) 2019; 182 X Wang (12691_CR45) 2019; 47 K Kawasaki (12691_CR52) 2020; 158 AL Latif (12691_CR15) 2021; 12 D Hnisz (12691_CR46) 2013; 155 B Donati (12691_CR14) 2018; 17 RC Coombes (12691_CR53) 2023; 14 JH Choi (12691_CR1) 2021; 28 ZZ Zheng (12691_CR18) 2022; 50 HJ Liu (12691_CR20) 2023; 10 S Li (12691_CR7) 2021; 19 A Vaharautio (12691_CR23) 2014; 346 ZJ Cheng (12691_CR50) 2019; 40 M Wada (12691_CR59) 2020; 65 H Rahnamoun (12691_CR16) 2018; 25 S Shu (12691_CR13) 2016; 529 NC Daw (12691_CR39) 2015; 112 12691_CR33 S Li (12691_CR6) 2021; 20 C Shi (12691_CR19) 2020; 22 PA Meyers (12691_CR34) 2008; 26 K Matsuoka (12691_CR5) 2020; 30 B Lu (12691_CR31) 2020; 18 H Song (12691_CR61) 2020; 126 EJ Faivre (12691_CR17) 2020; 578 C Shi (12691_CR41) 2019; 10 NM Marina (12691_CR35) 2016; 17 D Liao (12691_CR4) 2020; 22 C Li (12691_CR60) 2018; 9 YL Chen (12691_CR29) 2022; 12 L Wang (12691_CR21) 2017; 50 12691_CR22 C Wang (12691_CR51) 2020; 69 S Ferrari (12691_CR36) 2012; 30 N Gaspar (12691_CR38) 2021; 22 L Ma (12691_CR56) 2022; 90 YX See (12691_CR48) 2019; 35 YI Kim (12691_CR32) 2023; 13 G Bacci (12691_CR3) 2008; 98 A Briccoli (12691_CR40) 2010; 19 HP Mohammad (12691_CR8) 2019; 25 N Tasdemir (12691_CR25) 2016; 6 J Gill (12691_CR2) 2021; 18 YY Jiang (12691_CR43) 2017; 66 C Zheng (12691_CR47) 2020; 20 DH Lee (12691_CR42) 2015; 136 ER Zanella (12691_CR58) 2022; 19 12691_CR55 M Nilashi (12691_CR30) 2019; 12 TH Pillow (12691_CR27) 2020; 15 J Zhang (12691_CR44) 2020; 26 M Feng (12691_CR49) 2023; 42 J Zhao (12691_CR10) 2019; 38 LM Sternicki (12691_CR28) 2021; 16 F Fang (12691_CR9) 2022; 41 XY Wei (12691_CR64) 2023; 12 A Stathis (12691_CR12) 2018; 8 MK Jang (12691_CR54) 2005; 19 12691_CR62 N Gaspar (12691_CR37) 2018; 88 GH Li (12691_CR24) 2021; 40 HI Suzuki (12691_CR26) 2017; 168 CJ Diehl (12691_CR57) 2022; 51 |
| References_xml | – volume: 88 start-page: 57 year: 2018 ident: 12691_CR37 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2017.09.036 contributor: fullname: N Gaspar – volume: 38 start-page: 252 issue: 1 year: 2019 ident: 12691_CR10 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-019-1246-4 contributor: fullname: J Zhao – volume: 19 start-page: 719 issue: 11 year: 2022 ident: 12691_CR58 publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-022-00682-6 contributor: fullname: ER Zanella – volume: 50 start-page: 19 issue: 1 year: 2017 ident: 12691_CR21 publication-title: Biol Res doi: 10.1186/s40659-017-0124-9 contributor: fullname: L Wang – volume: 18 start-page: 609 issue: 10 year: 2021 ident: 12691_CR2 publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-021-00519-8 contributor: fullname: J Gill – volume: 136 start-page: 2055 issue: 9 year: 2015 ident: 12691_CR42 publication-title: Int J Cancer doi: 10.1002/ijc.29269 contributor: fullname: DH Lee – volume: 25 start-page: 687 issue: 8 year: 2018 ident: 12691_CR16 publication-title: Nat Struct Mol Biol doi: 10.1038/s41594-018-0102-0 contributor: fullname: H Rahnamoun – volume: 9 start-page: 1009 issue: 10 year: 2018 ident: 12691_CR60 publication-title: Cell Death Dis doi: 10.1038/s41419-018-1030-y contributor: fullname: C Li – volume: 25 start-page: 403 issue: 3 year: 2019 ident: 12691_CR8 publication-title: Nat Med doi: 10.1038/s41591-019-0376-8 contributor: fullname: HP Mohammad – volume: 182 start-page: 111633 year: 2019 ident: 12691_CR11 publication-title: Eur J Med Chem doi: 10.1016/j.ejmech.2019.111633 contributor: fullname: D Chen – volume: 22 start-page: 1312 issue: 9 year: 2021 ident: 12691_CR38 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(21)00387-9 contributor: fullname: N Gaspar – volume: 20 start-page: 161 issue: 1 year: 2021 ident: 12691_CR6 publication-title: Mol Cancer doi: 10.1186/s12943-021-01453-0 contributor: fullname: S Li – volume: 18 start-page: 57 issue: 1 year: 2020 ident: 12691_CR31 publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-19-0470 contributor: fullname: B Lu – ident: 12691_CR22 doi: 10.1084/jem.20190668 – volume: 14 start-page: 4444 issue: 1 year: 2023 ident: 12691_CR53 publication-title: Nat Commun doi: 10.1038/s41467-023-40061-y contributor: fullname: RC Coombes – volume: 40 start-page: 174 issue: 1 year: 2021 ident: 12691_CR24 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-021-01974-y contributor: fullname: GH Li – volume: 90 start-page: 431 issue: 6 year: 2022 ident: 12691_CR56 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-022-04483-7 contributor: fullname: L Ma – volume: 578 start-page: 306 issue: 7794 year: 2020 ident: 12691_CR17 publication-title: Nature doi: 10.1038/s41586-020-1930-8 contributor: fullname: EJ Faivre – volume: 19 start-page: 193 issue: 4 year: 2010 ident: 12691_CR40 publication-title: Surg Oncol doi: 10.1016/j.suronc.2009.05.002 contributor: fullname: A Briccoli – volume: 40 start-page: 814 issue: 6 year: 2019 ident: 12691_CR50 publication-title: Acta Pharmacol Sin doi: 10.1038/s41401-018-0187-3 contributor: fullname: ZJ Cheng – volume: 529 start-page: 413 issue: 7586 year: 2016 ident: 12691_CR13 publication-title: Nature doi: 10.1038/nature16508 contributor: fullname: S Shu – ident: 12691_CR62 doi: 10.3390/ijms20184482 – volume: 20 start-page: 2557 issue: 3 year: 2020 ident: 12691_CR47 publication-title: Oncol Lett doi: 10.3892/ol.2020.11855 contributor: fullname: C Zheng – volume: 26 start-page: 633 issue: 4 year: 2008 ident: 12691_CR34 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.14.0095 contributor: fullname: PA Meyers – volume: 112 start-page: 278 issue: 2 year: 2015 ident: 12691_CR39 publication-title: Br J Cancer doi: 10.1038/bjc.2014.585 contributor: fullname: NC Daw – volume: 47 start-page: 11481 issue: 22 year: 2019 ident: 12691_CR45 publication-title: Nucleic Acids Res contributor: fullname: X Wang – volume: 12 start-page: 13 issue: 1 year: 2019 ident: 12691_CR30 publication-title: J Infect Public Health doi: 10.1016/j.jiph.2018.09.009 contributor: fullname: M Nilashi – volume: 158 start-page: 638 issue: 3 year: 2020 ident: 12691_CR52 publication-title: Gastroenterology doi: 10.1053/j.gastro.2019.10.009 contributor: fullname: K Kawasaki – volume: 50 start-page: 10230 issue: 18 year: 2022 ident: 12691_CR18 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkac778 contributor: fullname: ZZ Zheng – volume: 42 start-page: 44 issue: 1 year: 2023 ident: 12691_CR49 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-023-02615-2 contributor: fullname: M Feng – volume: 16 start-page: 2206 issue: 14 year: 2021 ident: 12691_CR28 publication-title: ChemMedChem doi: 10.1002/cmdc.202100113 contributor: fullname: LM Sternicki – volume: 10 start-page: 815 issue: 11 year: 2019 ident: 12691_CR41 publication-title: Cell Death Dis doi: 10.1038/s41419-019-2022-2 contributor: fullname: C Shi – ident: 12691_CR55 doi: 10.1155/2022/7912484 – volume: 17 start-page: 1396 issue: 10 year: 2016 ident: 12691_CR35 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30214-5 contributor: fullname: NM Marina – volume: 15 start-page: 17 issue: 1 year: 2020 ident: 12691_CR27 publication-title: ChemMedChem doi: 10.1002/cmdc.201900497 contributor: fullname: TH Pillow – volume: 35 start-page: 145 issue: 2 year: 2019 ident: 12691_CR48 publication-title: Trends Genet doi: 10.1016/j.tig.2018.11.007 contributor: fullname: YX See – volume: 28 start-page: 119 issue: 3 year: 2021 ident: 12691_CR1 publication-title: Adv Anat Pathol doi: 10.1097/PAP.0000000000000293 contributor: fullname: JH Choi – volume: 66 start-page: 1358 issue: 8 year: 2017 ident: 12691_CR43 publication-title: Gut doi: 10.1136/gutjnl-2016-311818 contributor: fullname: YY Jiang – volume: 30 start-page: 2112 issue: 17 year: 2012 ident: 12691_CR36 publication-title: J Clin Oncol doi: 10.1200/JCO.2011.38.4420 contributor: fullname: S Ferrari – volume: 41 start-page: 225 issue: 1 year: 2022 ident: 12691_CR9 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-022-02428-9 contributor: fullname: F Fang – volume: 13 start-page: 136 issue: 1 year: 2023 ident: 12691_CR32 publication-title: Cell Biosci doi: 10.1186/s13578-023-01088-2 contributor: fullname: YI Kim – volume: 98 start-page: 415 issue: 6 year: 2008 ident: 12691_CR3 publication-title: J Surg Oncol doi: 10.1002/jso.21140 contributor: fullname: G Bacci – volume: 19 start-page: 277 issue: 1 year: 2021 ident: 12691_CR7 publication-title: J Nanobiotechnol doi: 10.1186/s12951-021-01028-7 contributor: fullname: S Li – volume: 51 start-page: 8216 issue: 19 year: 2022 ident: 12691_CR57 publication-title: Chem Soc Rev doi: 10.1039/D2CS00387B contributor: fullname: CJ Diehl – volume: 30 start-page: 885 issue: 10 year: 2020 ident: 12691_CR5 publication-title: Cell Res doi: 10.1038/s41422-020-0370-1 contributor: fullname: K Matsuoka – volume: 12 start-page: 241 issue: 1 year: 2021 ident: 12691_CR15 publication-title: Nat Commun doi: 10.1038/s41467-020-20378-8 contributor: fullname: AL Latif – volume: 8 start-page: 24 issue: 1 year: 2018 ident: 12691_CR12 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-17-0605 contributor: fullname: A Stathis – volume: 10 start-page: e2207439 issue: 16 year: 2023 ident: 12691_CR20 publication-title: Adv Sci (Weinh) doi: 10.1002/advs.202207439 contributor: fullname: HJ Liu – volume: 168 start-page: 1000 issue: 6 year: 2017 ident: 12691_CR26 publication-title: Cell doi: 10.1016/j.cell.2017.02.015 contributor: fullname: HI Suzuki – volume: 126 start-page: 109941 year: 2020 ident: 12691_CR61 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2020.109941 contributor: fullname: H Song – volume: 10 start-page: 2115 issue: 1 year: 2019 ident: 12691_CR63 publication-title: Nat Commun doi: 10.1038/s41467-019-09676-y contributor: fullname: Y Perone – volume: 12 start-page: 33 issue: 1 year: 2022 ident: 12691_CR29 publication-title: Cell Biosci doi: 10.1186/s13578-022-00769-8 contributor: fullname: YL Chen – volume: 346 start-page: 1291 issue: 6215 year: 2014 ident: 12691_CR23 publication-title: Science doi: 10.1126/science.aaa3247 contributor: fullname: A Vaharautio – volume: 69 start-page: 727 issue: 4 year: 2020 ident: 12691_CR51 publication-title: Gut doi: 10.1136/gutjnl-2019-318506 contributor: fullname: C Wang – volume: 65 start-page: 1019 issue: 11 year: 2020 ident: 12691_CR59 publication-title: J Hum Genet doi: 10.1038/s10038-020-0795-x contributor: fullname: M Wada – volume: 17 start-page: 164 issue: 1 year: 2018 ident: 12691_CR14 publication-title: Mol Cancer doi: 10.1186/s12943-018-0915-9 contributor: fullname: B Donati – volume: 155 start-page: 934 issue: 4 year: 2013 ident: 12691_CR46 publication-title: Cell doi: 10.1016/j.cell.2013.09.053 contributor: fullname: D Hnisz – volume: 12 start-page: 13991 issue: 13 year: 2023 ident: 12691_CR64 publication-title: Cancer Med doi: 10.1002/cam4.6040 contributor: fullname: XY Wei – volume: 22 start-page: 1114 issue: 8 year: 2020 ident: 12691_CR19 publication-title: Neuro Oncol doi: 10.1093/neuonc/noaa084 contributor: fullname: C Shi – volume: 19 start-page: 523 issue: 4 year: 2005 ident: 12691_CR54 publication-title: Mol Cell doi: 10.1016/j.molcel.2005.06.027 contributor: fullname: MK Jang – ident: 12691_CR33 doi: 10.15252/emmm.201809408 – volume: 22 start-page: 868 issue: 7 year: 2020 ident: 12691_CR4 publication-title: Nat Cell Biol doi: 10.1038/s41556-020-0522-z contributor: fullname: D Liao – volume: 26 start-page: 2681 issue: 11 year: 2020 ident: 12691_CR44 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-19-1418 contributor: fullname: J Zhang – volume: 6 start-page: 612 issue: 6 year: 2016 ident: 12691_CR25 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-16-0217 contributor: fullname: N Tasdemir |
| SSID | ssj0017808 |
| Score | 2.4637828 |
| Snippet | Osteosarcoma (OS) is one of the most common primary malignant tumors of bone in children, which develops from osteoblasts and typically occurs during the rapid... Background Osteosarcoma (OS) is one of the most common primary malignant tumors of bone in children, which develops from osteoblasts and typically occurs... BackgroundOsteosarcoma (OS) is one of the most common primary malignant tumors of bone in children, which develops from osteoblasts and typically occurs during... Abstract Background Osteosarcoma (OS) is one of the most common primary malignant tumors of bone in children, which develops from osteoblasts and typically... |
| SourceID | doaj pubmedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 928 |
| SubjectTerms | Animals Antimitotic agents Antineoplastic agents Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Antitumor activity Apoptosis Apoptosis - drug effects Bone cancer Bone growth Bone Neoplasms - drug therapy Bone Neoplasms - genetics Bone Neoplasms - metabolism Bone Neoplasms - pathology Bone tumors BRD4 Bromodomain Containing Proteins Carcinogenesis Care and treatment Cell culture Cell cycle Cell Cycle Proteins - antagonists & inhibitors Cell Cycle Proteins - genetics Cell Cycle Proteins - metabolism Cell Line, Tumor Cell proliferation Cell Proliferation - drug effects Cell size Chromatin Cloning Development and progression Diagnosis Dosage and administration Enhancer Elements, Genetic Enhancers Epigenetics Flow cytometry Gene Expression Regulation, Neoplastic - drug effects Gene regulation Genes Genetic aspects Health aspects Humans KRT80 Medical prognosis Medical research Metastases Metastasis Mice Mice, Nude Microwaves Osteosarcoma Osteosarcoma - drug therapy Osteosarcoma - genetics Osteosarcoma - metabolism Osteosarcoma - pathology Osteosarcoma cells PROTAC RNA polymerase Sarcoma SEs Toxicity Transcription Factors - antagonists & inhibitors Transcription Factors - genetics Transcription Factors - metabolism Tumorigenesis Tumors Xenograft Model Antitumor Assays Xenografts |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9JL6btu0lYthR6KifySpeMmbJIWkpZ0C7kJSZa7hsRe7DV0_31nZO-ypodecjJYY2HPQzNjzXwi5JOWVsssKUKdsxQSlMiFMsvB8CKD8HAslyU2J19e8Ytf6beb7GbvqC-sCRvggQfGHTMe61ILaR23MFUmmMlSHukkiorUptavvkxuk6lx_yAXTGxbZAQ_7mAVFtiJjBh9XEbhZuKGPFr_v2vynlOaFkzueaCzJ-TxGDrS2fDKT8kDVz8jDy_HzfHn5A-InJ7MF_TH9ffF7JRW9bIyYLAtPb-ah5D106LqVrd601FgZxWu-zsYGws6qNnQoSocfBnt-pVrQ1cvUSfajrbDifWuoKBvDmam2BvSdGAlzZ1-QRZn88XpRTgerBBaMMF1yKUuJNMOcpkiTrRFRB64pkZGmpkix6OETCachdw5c4VIrImsSVFucQmSfUkO6qZ2rwkFjmgdQZSnHbg5LUzsRJFIlplS2DgtA_Jly2a1GuAzlE87BFeDUBQIRXmhqE1ATlASO0qEvvY3QCHUqBDqfwoRkPcoRzX0ke4MWM0ES_wuYRKQj54C4S9qrK_5rfuuU19_Xk-IPo9EZQMyt3psV4DvRsSsCeXRhBLs006HtwqlxvWhUwmEaTH4GRYH5MNuGJ_EmrfaNT3SiBz_yuEUrwb923EGWAxM5iIgYqKZE9ZNR-pq6dHDMcCOZSbe3AezD8mjGK3KV0QekYN127u3EKWtzTtvkH8B0zo32A priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgSIgXND4XNsAgJB5QtDif9hPqpo6BtIFGkfpm2Y6zRmJJSRqJ_vfcJW5YhMRTpfoapXf3u_PZ90HIOyWMEkmU-yoLYghQmPVFkgHwmMb2cEEmCixOvrhMz3_EX5bJ0h24tS6tcmcTe0Od1wbPyI8jcGwhIDMIP65_-Tg1Cm9X3QiNu-QeC4MUU7qy5RhwsYwHfFcow9PjFmwxx3pk7NSXCuZvJ86o79n_r2W-5ZqmaZO3_NDZPnnoNpB0Nkj8Ebljq8fk_oW7In9CfoPg6cl8Qb9dfV3MTmlZrUoNsG3op8u5D7E_zct2_VNtWwpMLf1NdwNrLq2D6i0dcsPBo9G2W9vGt9UKNaNpaTPMrbc5Ba2z8GSKFSJ1C1ipb9RTsjibL07PfTdewTcAxI2fCpWLQFmIaPIwUgb78sBnrAVTgc4zHCikE24NRNCJzXlkNDM6RumFBcj3Gdmr6soeEAocUYrBXk9ZcHaK69DyPBJBogtuwrjwyIcdm-V6aKIh--CDp3IQigShyF4ocuuRE5TESIkNsPsv6uZaOjzJIA1VobgwNjWgYQmHV41TpiLG8tjExiOvUY5yqCYdYSxnPIj6u8LII297CmyCUWGWzbXq2lZ-_n41IXrviIoaZG6UK1qA_419syaURxNKQKmZLu8USjor0cq_Ou2RN-My_hIz3ypbd0jDMzybw0c8H_Rv5AywGJicco_wiWZOWDddqcpV30Mct9mhSPiL_7_XIXkQIl76jMcjsrdpOvsSdmEb_aqH2h_e6S-o priority: 102 providerName: ProQuest |
| Title | The BET PROTAC inhibitor GNE-987 displays anti-tumor effects by targeting super-enhancers regulated gene in osteosarcoma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39090568 https://www.proquest.com/docview/3091291102 https://www.proquest.com/docview/3087354023 https://pubmed.ncbi.nlm.nih.gov/PMC11292958 https://doaj.org/article/062afa89ce6c401580b5461a311d4c4c |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9NAEF_uThBfxG-jZ11F8EFyzXc2j23peQqtpVYoviy7m801cE1K0oL9753ZJOWCb7600J2EdH7z29nJzswS8kkkSiShn9oidgIIUFxtJ2EMxHMltodz4iTD4uTZPLr5FXxfh-szEnW1MCZpX8n8qrjbXhX5xuRW7rZq2OWJDRezCa4RvCRkw3NyDhbaxejt3kHMHNaVx7BoWMMMzLAKGfvzRYlrH3suyHTq_3c-vueQ-smS97zP9RPyuF020lHzeE_JmS6ekYezdmP8OfkDcNPxdEUXyx-r0YTmxSaXQNaKfp1PbYj4aZrXuztxrCmoMrf3hy2MtckcVB5pkxEOfozWh52ubF1s0B6qmlbNafU6pWBrGu5MsS6krIEh5Va8IKvr6WpyY7eHKtgK6Le3o0SkiSM0xDGp5wuF3XjgO5CJKxyZxniMkAyZVhA3hzplvpKukgFi5mWA6ktyUZSFfk0oaEQIF1Z4QoOLE0x6mqV-4oQyY8oLMot86dTMd03rDG5CDhbxBhQOoHADCj9aZIxInCSx7bX5oaxueQs-dyJPZIIlSkcK7Cpk8KhB5ArfddNABcoi7xFH3tSQnsjLR8zxzQ6hb5GPRgJbXxSYW3MrDnXNv_1c9oQ-t0JZCZgr0ZYqwP_Gblk9ycueJHBT9Yc7g-Lt3FBzH5ZoHvgYx7PIh9MwXon5boUuDyjDYnwjh7d41djfSTOgYlByxCzCepbZU11_BIhkOod3xHnz_5e-JY885JLJgbwkF_vqoN_BumwvB0DGdTwgD8bT-WI5MG834HM5_j0wBP0LGCA7-A |
| link.rule.ids | 230,315,730,783,787,867,888,2109,12068,21400,27936,27937,31731,31732,33756,33757,43322,43817,53804,53806 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgSMDLxOfIGMwgJB5QtHzHfkLd1NHBWtAIUt8s23HWSiwpSSvR_567xA2LkHiqVF-j9D599t3vCHknuZY8DnNXpl4ECYpvXB6nYHi-Qng4L-UFNidPZ8nkR_R5Hs_tgVtjyyp3PrF11Hml8Yz8JITAFoBlesHH1S8Xp0bh7aodoXGX3EMcLpxgkM77hMtPmcd2jTIsOWnAFzPsR0akvoT77nYQjFrM_n89863QNCybvBWHzh-RfbuBpKNO4o_JHVM-Ifen9or8KfkNgqen44x-u_qajc7oslwsFZhtTT_Nxi7k_jRfNqufcttQYOrSXW9uYM2WdVC1pV1tOEQ02mxWpnZNuUDNqBtad3PrTU5B6ww8mWKHSNWArVQ38hnJzsfZ2cS14xVcDYa4dhMuc-5JAxlNHoRSIy4PfEaK-9JTeYoDhVTMjIYMOjY5C7XytYpQekEB8n1O9sqqNC8IBY5I6cNeTxoIdpKpwLA85F6sCqaDqHDIhx2bxaoD0RBt8sES0QlFgFBEKxSxdcgpSqKnRADs9ouqvhbWnoSXBLKQjGuTaNCwmMGrRokvQ9_PIx1phxyjHEXXTdqbsRgxL2zvCkOHvG0pEASjxCqba7lpGnHx_WpA9N4SFRXIXEvbtAD_G3GzBpRHA0qwUj1c3imUsF6iEX912iFv-mX8JVa-labaIA1L8WwOH3HQ6V_PGWAxMDlhDmEDzRywbrhSLhcthjhuswMes8P_v9cxeTDJppfi8mL25SV5GKDttNWPR2RvXW_MK9iRrdXr1uz-ADJbMo8 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgSBMv3C-BwQxC4gGlzT32Y1daNqBlGkWaxINlO04bsSZV0kiUX89x4lQLvO2pUn0SJT7fuTj-zjFC7ziVnIZ-YvPYCWCB4iqbhjEYnit0ezgnpqkuTp7No9MfwefL8NKwKitDq8ylyAb51XqQZ6uGW7lZy2HHExuez8Y6R_BoSIabJB3eRnfAaJ2oW6mbHYSYOKQrkiHRsAI_THQtsu7SF1HX3vUCUdOv_3-vfC0s9SmT12LQ9D762T19Sz35Nai3YiD__NPY8Wav9wDdM6kpHrUyD9EtlT9ChzOz-f4Y_QZI4ZPJAp9ffFuMxjjLV5kAh1DiT_OJTUmMk6zaXPFdhUFdmb2t1zBmCCNY7HDLOodYiat6o0pb5SuNubLCpVrqY8RUggHPCu6Mde1JUYEVFmv-BC2mk8X41DYHN9gSTHxrR5Qn1OEK1kqJ53OpO_7AbyCoyx2RxPqoIhESJWFtHqqE-FK4UgQaF14KyHmKDvIiV88Rhvnm3IUskisIo5wIT5HEp04oUiK9ILXQh06JbNO252DNsoZErFU5A5WzRuVsZ6ETree9pG6t3fxRlEtmNMCcyOMpJ1SqSAJ2QwKPGkQu9103CWQgLXSsUcLaOtW9g2Aj4vjNLqRvobeNhG6vkWv-zpLXVcXOvl_0hN4bobQAREluyiHgvXVHrp7kUU8S7F_2hzu4MuN_KuZDGuhBHHM8C73ZD-srNacuV0WtZUisv_rpWzxr0b2fGZhimOSIWIj0cN-buv4IoLnpTt6h98XNLz1Gh-cfp-zr2fzLS3TX00bbUC6P0MG2rNUrSAO34nVj738BoixcHw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+BET+PROTAC+inhibitor+GNE-987+displays+anti-tumor+effects+by+targeting+super-enhancers+regulated+gene+in+osteosarcoma&rft.jtitle=BMC+cancer&rft.au=Wu%2C+Di&rft.au=Yin%2C+Hongli&rft.au=Yang%2C+Chun&rft.au=Zhang%2C+Zimu&rft.date=2024-08-01&rft.pub=BioMed+Central&rft.eissn=1471-2407&rft.volume=24&rft.spage=1&rft_id=info:doi/10.1186%2Fs12885-024-12691-y |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |